m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT03634				[1], [2]
Histone modification H3K27me3 EZH2 miR-338-5p Indirect Enhancement m⁶A modification BCL2 BCL2 METTL3 Methylation : m⁶A sites
m6A Regulator	Methyltransferase-like 3 (METTL3)			WRITER	Regulator Info
m6A Target	Apoptosis regulator Bcl-2 (BCL2)				Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	Histone modification (HistMod)
Epigenetic Regulator	Histone-lysine N-methyltransferase EZH2 (EZH2)			WRITER	View Details
Regulated Target	Histone H3 lysine 27 trimethylation (H3K27me3)				View Details
Downstream Gene	miR-338-5p				View Details
Crosstalk Relationship	Histone modification → m6A			Enhancement
Crosstalk Mechanism	histone modification indirectly regulates m6A modification through downstream signaling pathways
Crosstalk Summary	Collectively, EZH2 downregulated hsa-miR-338-5p through Histone H3 lysine 27 trimethylation (H3K27me3), which in turn impaired miR-338-5p-dependent METTL3 inhibition and enhanced CDCP1 translation, therefore contributing to the development of GC. Down-regulation of METTL3 inhibits the proliferation and mobility of human gastric cancer cells and leads to inactivation of the AKT signaling pathway, suggesting that METTL3 is a potential target for the treatment of human gastric cancer. METTL3 knockdown decreased Apoptosis regulator Bcl-2 (BCL2) and increased Bax and active Caspase-3 in gastric cancer cells, which suggested the apoptotic pathway was activated. METTL3 led to inactivation of the AKT signaling pathway in human gastric cancer cells, including decreased phosphorylation levels of AKT and expression of down-stream effectors p70S6K and Cyclin D1.
Responsed Disease	Gastric cancer		ICD-11: 2B72		Disease Info
Pathway Response	Apoptosis				hsa04210
Pathway Response	PI3K-Akt signaling pathway				hsa04151
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
In-vitro Model	AGS	Gastric adenocarcinoma	Homo sapiens		CVCL_0139
In-vitro Model	MKN45	Gastric adenocarcinoma	Homo sapiens		CVCL_0434

Full List of Potential Compound(s) Related to This m6A-centered Crosstalk

Apoptosis regulator Bcl-2 (BCL2)		49 Compound(s) Regulating the Target	Click to Show/Hide the Full List
Compound Name	GDC-0199		Approved	[3]
MOA	Modulator
Activity	Ki < 0.01 nM
External Link	CID: 49846579 TTD: D00PBX DrugBank: DB11581
Compound Name	MCI-186		Approved	[4]
Synonyms	Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one Click to Show/Hide
MOA	Regulator (upregulator)
External Link	CID: 4021 TTD: D06DLI DrugBank: DB12243
Compound Name	Taxol		Approved	[5]
Synonyms	C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR,betaS),11alpha,12alpha,12aalpha,12balpha))- Click to Show/Hide
MOA	Modulator
External Link	CID: 36314 TTD: D0C4RB DrugBank: DB01229
Compound Name	Oblimersen		Phase 3	[6]
MOA	Inhibitor
External Link	CID: 118984457 TTD: D05RJP
Compound Name	RG7601		Phase 3	[3]
MOA	Modulator
External Link	TTD: D0I6OI
Compound Name	Taxol/Paraplatin/Herceptin		Phase 3	[7]
Synonyms	Paclitaxel/carboplatin/trastuzumab Click to Show/Hide
MOA	Modulator
External Link	TTD: D0J6PY
Compound Name	ABT-263		Phase 3	[8]
Synonyms	Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide Click to Show/Hide
MOA	Inhibitor
Activity	Ki < 0.01 nM
External Link	CID: 24978538 TTD: D06ETI DrugBank: DB12340
Compound Name	Thymoquinone		Phase 2/3	[9]
Synonyms	490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI Click to Show/Hide
MOA	Inhibitor
External Link	CID: 10281 TTD: DY4OZ6
Compound Name	Gossypol		Phase 2	[10]
Synonyms	303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate Click to Show/Hide
MOA	Regulator
Activity	Ki = 170 nM
External Link	CID: 3503 TTD: D0Z0HH DrugBank: DB13044
Compound Name	PI-88/Taxotere		Phase 2	[11]
Synonyms	PI-88/docetaxel Click to Show/Hide
MOA	Modulator
External Link	TTD: D0K8LB
Compound Name	Obatoclax		Phase 2	[12]
Synonyms	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7 Click to Show/Hide
MOA	Inhibitor
Activity	EC50 = 300 nM
External Link	CID: 11404337 TTD: D02OZK DrugBank: DB12191
Compound Name	APG-2575		Phase 1/2	[13]
Synonyms	Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 137355972 TTD: D2Y7ZG
Compound Name	APG-1252		Phase 1/2	[14]
MOA	Inhibitor
External Link	TTD: D4WN2M
Compound Name	AZD0466		Phase 1/2	[15]
MOA	Inhibitor
External Link	TTD: DQ1P6X
Compound Name	BCL201		Phase 1	[16]
MOA	Inhibitor
External Link	TTD: D0C6YQ
Compound Name	Pc4		Phase 1	[17]
Synonyms	Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC Click to Show/Hide
MOA	Agonist
External Link	TTD: D0L2YF
Compound Name	BGB-11417		Phase 1	[18]
MOA	Inhibitor
External Link	TTD: D74BRK
Compound Name	LP-108		Phase 1	[19]
External Link	TTD: DBY42T
Compound Name	LOXO-338		Phase 1	[20]
MOA	Inhibitor
External Link	TTD: DJLX87
Compound Name	VOB560		Phase 1	[21]
Synonyms	S 65487 Click to Show/Hide
MOA	Inhibitor
External Link	TTD: DP63FS
Compound Name	AI-850		Phase 1	[22]
MOA	Modulator
External Link	TTD: D03UDW
Compound Name	Irofulven/Taxotere		Phase 1	[23]
Synonyms	MGI 114/docetaxel Click to Show/Hide
MOA	Modulator
External Link	TTD: D05CHN
Compound Name	Indole-based analog 2		Patented	[24]
Synonyms	PMID27744724-Compound-16 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 7100 nM
External Link	TTD: D0C2DV
Compound Name	PMID27744724-Compound-10		Patented	[24]
MOA	Inhibitor
Activity	Ki = 5800 nM
External Link	TTD: D0IS8R
Compound Name	PMID27744724-Compound-21		Patented	[24]
MOA	Inhibitor
Activity	Ki = 2000 nM
External Link	TTD: D0J9FN
Compound Name	Indole-based analog 3		Patented	[24]
Synonyms	PMID27744724-Compound-17 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 1900 nM
External Link	TTD: D0MZ7I
Compound Name	PMID27744724-Compound-18		Patented	[24]
MOA	Inhibitor
Activity	Ki = 33000 nM
External Link	TTD: D0TU3N
Compound Name	ABT-737		Terminated	[25]
Synonyms	852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide Click to Show/Hide
MOA	Inhibitor
Activity	Ki < 0.6 nM
External Link	CID: 11228183 TTD: D0L8WH
Compound Name	WL-276		Investigative	[26]
MOA	Modulator
External Link	TTD: D04HAA
Compound Name	N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide		Investigative	[27]
Synonyms	CHEMBL214965; SCHEMBL15313847 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 5000 nM
External Link	CID: 16090304 TTD: D04RTY
Compound Name	5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine		Investigative	[28]
MOA	Inhibitor
Activity	IC50 = 1600 nM
External Link	CID: 135468219 TTD: D06AQG
Compound Name	modified HA14-1 compounds (cancer)		Investigative	[29]
Synonyms	Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals Click to Show/Hide
MOA	Modulator
External Link	TTD: D0S0YV
Compound Name	Apogossypol		Investigative	[30]
Synonyms	BI-79D10; BI-97C1; CNDO-103; CNDO-133 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 640 nM
External Link	CID: 454878 TTD: D0V7PX
Compound Name	2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide		Investigative	[27]
Synonyms	CHEMBL214839; BDBM50196033 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 7000 nM
External Link	CID: 16090303 TTD: D0X0CS
Compound Name	4,5-dibenzylbenzene-1,2-diol		Investigative	[31]
Synonyms	4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 4700 nM
External Link	CID: 379493 TTD: D0D6BH
Compound Name	TW-37		Investigative	[27]
Synonyms	877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 200 nM
External Link	CID: 11455910 TTD: D00LHS
Compound Name	QEDIIRNIARHLAQVGDSMDR		Investigative	[27]
MOA	Inhibitor
External Link	CID: 77280325 TTD: D0S6IW
Compound Name	PNT-2258		Phase 2	[32]
External Link	TTD: D07ACL
Compound Name	Beclanorsen		Phase 1/2	[32]
Synonyms	SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris Click to Show/Hide
External Link	TTD: D00GAM
Compound Name	BP1002		Phase 1	[32]
External Link	TTD: DBPV74
Compound Name	G3139 + Thalidomide		Investigative	[32]
External Link	CID: 91865905 TTD: D00DDR
Compound Name	G3139 + Irinotecan		Investigative	[32]
External Link	CID: 91865905 TTD: D05IAN
Compound Name	G3139 + G-CSF		Investigative	[32]
External Link	CID: 91865905 TTD: D0B0HK
Compound Name	G3139 + Fludarabine		Investigative	[32]
External Link	CID: 91865905 TTD: D0LM3T
Compound Name	BP-100-1.02		Investigative	[32]
Synonyms	Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path Click to Show/Hide
External Link	TTD: D0Q5NZ
Compound Name	G3139 + Paclitaxel		Investigative	[32]
External Link	CID: 91865905 TTD: D0S1FM
Compound Name	G3139 + Dexamethasone		Investigative	[32]
External Link	CID: 91865905 TTD: D0W8ZE
Compound Name	G3139 + Dacarbazine		Investigative	[32]
External Link	CID: 91865905 TTD: D0XU1I
Compound Name	G3139 + cytarabine (ARA-C)		Investigative	[32]
External Link	CID: 91865905 TTD: D0XU9F
Histone-lysine N-methyltransferase EZH2 (EZH2)		74 Compound(s) Regulating the Target	Click to Show/Hide the Full List
Compound Name	Tazemetostat		Approved	[33]
Synonyms	EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)- Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 2.5 nM
External Link	CID: 66558664 TTD: D00EQL DrugBank: DB12887
Compound Name	DS-3201b		Phase 2	[34]
Synonyms	Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 126481870 TTD: DNM79H
Compound Name	CPI-1205		Phase 1/2	[16]
Synonyms	HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 78320408 TTD: D0E6AG DrugBank: DB14581
Compound Name	SHR2554		Phase 1/2	[35]
MOA	Inhibitor
External Link	TTD: DM5X0L
Compound Name	CPI-0209		Phase 1/2	[36]
MOA	Inhibitor
External Link	TTD: DXL38G
Compound Name	GSK2816126		Phase 1	[37]
Synonyms	GSK 126; GSK-126 Click to Show/Hide
MOA	Modulator
Activity	Ki = 0.5 nM
External Link	CID: 68210102 TTD: D05FIJ
Compound Name	PF-06821497		Phase 1	[38]
Synonyms	UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD Click to Show/Hide
MOA	Inhibitor
External Link	CID: 118572065 TTD: DI1L7M DrugBank: DB14799
Compound Name	DS-3201		Phase 1	[16]
Synonyms	QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione Click to Show/Hide
MOA	Inhibitor
External Link	CID: 22627096 TTD: D0LG8T
Compound Name	HH2853		Phase 1	[39]
MOA	Inhibitor
External Link	TTD: D6EU7R
Compound Name	PMID28394193-Compound-33		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 100 nM
External Link	CID: 121305270 TTD: D03MYI
Compound Name	PMID28394193-Compound-Figure3bI		Patented	[40]
MOA	Inhibitor
External Link	TTD: D04PCW
Compound Name	PMID28394193-Compound-35		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 10 nM
External Link	TTD: D05MAR
Compound Name	PMID28394193-Compound-54		Patented	[40]
MOA	Inhibitor
External Link	TTD: D07CZI
Compound Name	PMID28394193-Compound-24		Patented	[40]
MOA	Inhibitor
Activity	IC50 < 1000 nM
External Link	CID: 117807842 TTD: D08MXO
Compound Name	PMID28394193-Compound-27		Patented	[40]
MOA	Inhibitor
Activity	IC50 < 1000 nM
External Link	CID: 76684269 TTD: D09GFF
Compound Name	PMID28394193-Compound-25		Patented	[40]
MOA	Inhibitor
Activity	IC50 < 1000 nM
External Link	CID: 117807842 TTD: D09PQQ
Compound Name	PMID28394193-Compound-50		Patented	[40]
MOA	Inhibitor
Activity	IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link	CID: 118580552 TTD: D0A0VH
Compound Name	PMID28394193-Compound-47		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 2 nM; Ki < 1 nM
External Link	CID: 118616529 TTD: D0B4TX
Compound Name	PMID28394193-Compound-21		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0BL8W
Compound Name	PMID28394193-Compound-41		Patented	[40]
MOA	Inhibitor
External Link	CID: 118101320 TTD: D0BT6Y
Compound Name	PMID28394193-Compound-53		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 80 nM
External Link	CID: 121322599 TTD: D0CH4O
Compound Name	PMID28394193-Compound-Figure5aVIII		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0D1QD
Compound Name	PMID28394193-Compound-38		Patented	[40]
MOA	Inhibitor
External Link	CID: 78320108 TTD: D0DQ6N
Compound Name	PMID28394193-Compound-51		Patented	[40]
MOA	Inhibitor
Activity	IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link	CID: 118580509 TTD: D0FC9J
Compound Name	PMID28394193-Compound-31		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 20 nM
External Link	TTD: D0FI3A
Compound Name	PMID28394193-Compound-42		Patented	[40]
MOA	Inhibitor
External Link	CID: 118096643 TTD: D0H4HR
Compound Name	PMID28394193-Compound-15		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0KR2T
Compound Name	PMID28394193-Compound-52		Patented	[40]
MOA	Inhibitor
Activity	IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link	CID: 118580510 TTD: D0LR5O
Compound Name	PMID28394193-Compound-32		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 500 nM
External Link	TTD: D0M1TG
Compound Name	PMID28394193-Compound-23		Patented	[40]
MOA	Inhibitor
Activity	IC50 < 1000 nM
External Link	CID: 117807623 TTD: D0M9BY
Compound Name	PMID28394193-Compound-29		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 100 nM
External Link	TTD: D0MH8G
Compound Name	PMID28394193-Compound-30		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 16 nM
External Link	TTD: D0MO2X
Compound Name	PMID28394193-Compound-39		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0MZ8D
Compound Name	PMID28394193-Compound-49		Patented	[40]
MOA	Inhibitor
Activity	IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link	CID: 118572078 TTD: D0PB6T
Compound Name	PMID28394193-Compound-43		Patented	[40]
MOA	Inhibitor
External Link	CID: 118096796 TTD: D0PI5O
Compound Name	PMID28394193-Compound-40		Patented	[40]
MOA	Inhibitor
External Link	CID: 118095598 TTD: D0QH1J
Compound Name	PMID28394193-Compound-Figure3bIII		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0R2TQ
Compound Name	PMID28394193-Compound-36		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 316 nM
External Link	TTD: D0RD5P
Compound Name	PMID28394193-Compound-28		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 32 nM
External Link	CID: 91884579 TTD: D0S4OP
Compound Name	PMID28394193-Compound-22		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0SQ1R
Compound Name	PMID28394193-Compound-18		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0SY6P
Compound Name	PMID28394193-Compound-16		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0T8QL
Compound Name	PMID28394193-Compound-44		Patented	[40]
MOA	Inhibitor
External Link	CID: 118096614 TTD: D0U9OH
Compound Name	PMID28394193-Compound-20		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0UG5O
Compound Name	PMID28394193-Compound-19		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0VF0M
Compound Name	PMID28394193-Compound-37		Patented	[40]
MOA	Inhibitor
External Link	CID: 78320107 TTD: D0W2KL
Compound Name	PMID28394193-Compound-Figure3bII		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0W4MW
Compound Name	PMID28394193-Compound-26		Patented	[40]
MOA	Inhibitor
Activity	IC50 < 1000 nM
External Link	CID: 75203283 TTD: D0Z0NC
Compound Name	PMID28394193-Compound-17		Patented	[40]
MOA	Inhibitor
External Link	TTD: D0Z0QS
Compound Name	PMID28394193-Compound-34		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 100 nM
External Link	TTD: D0Z7GN
Compound Name	PMID28394193-Compound-56		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 0.93 nM
External Link	TTD: D01PZZ
Compound Name	PMID28394193-Compound-46		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 5 nM
External Link	CID: 102593999 TTD: D0D4UH
Compound Name	PMID28394193-Compound-57		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 6.45 nM
External Link	TTD: D0G1JR
Compound Name	PMID28394193-Compound-14		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 21900 nM
External Link	CID: 90467336 TTD: D0GT7A
Compound Name	PMID28394193-Compound-12		Patented	[40]
MOA	Inhibitor
Activity	IC50 < 10 nM
External Link	TTD: D0H8VN
Compound Name	PMID26882240-Compound-1		Patented	[41]
MOA	Inhibitor
External Link	CID: 5712 TTD: D0L1TA
Compound Name	PMID28394193-Compound-55		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 8.13 nM
External Link	TTD: D0M4LK
Compound Name	PMID28394193-Compound-45		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 168000 nM
External Link	CID: 118607675 TTD: D0M8AA
Compound Name	PMID28394193-Compound-13		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 1470 nM
External Link	CID: 86765324 TTD: D0TA4N
Compound Name	EPZ005687		Investigative	[42]
Synonyms	EPZ-005687; EPZ 005687 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 60160561 TTD: D02BBA
Compound Name	EI1		Investigative	[43]
Synonyms	KB-145943 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 72199293 TTD: D02CIT
Compound Name	UNC1999		Investigative	[44]
Synonyms	UNC 1999; UNC-1999 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 72551585 TTD: D02YXP
Compound Name	MS1943		Investigative	[35]
Synonyms	2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide Click to Show/Hide
MOA	Degrader
External Link	CID: 139211327 TTD: D65IMT
Compound Name	GSK343		Investigative	[45]
Synonyms	compound 6 [PMID 24900432]; GSK 343 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 174 nM
External Link	CID: 71268957 TTD: D02TVQ
Compound Name	PMID28394193-Compound-11		Patented	[32]
External Link	TTD: D0MH5C
Compound Name	PMID28394193-Compound-10		Patented	[32]
External Link	TTD: D0MZ9P
Compound Name	PMID28394193-Compound-14		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 21900 nM
External Link	CID: 90467336 TTD: D0GT7A
Compound Name	PMID28394193-Compound-12		Patented	[40]
MOA	Inhibitor
Activity	IC50 < 10 nM
External Link	TTD: D0H8VN
Compound Name	PMID28394193-Compound-13		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 1470 nM
External Link	CID: 86765324 TTD: D0TA4N
Compound Name	PMID28394193-Compound-56		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 0.93 nM
External Link	TTD: D01PZZ
Compound Name	PMID28394193-Compound-46		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 5 nM
External Link	CID: 102593999 TTD: D0D4UH
Compound Name	PMID28394193-Compound-57		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 6.45 nM
External Link	TTD: D0G1JR
Compound Name	PMID28394193-Compound-55		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 8.13 nM
External Link	TTD: D0M4LK
Compound Name	PMID28394193-Compound-45		Patented	[40]
MOA	Inhibitor
Activity	IC50 = 168000 nM
External Link	CID: 118607675 TTD: D0M8AA
2B72: Gastric cancer		81 Compound(s) Regulating the Disease	Click to Show/Hide the Full List
Compound Name	Leniolisib		Approved	[46]
Synonyms	1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ Click to Show/Hide
External Link	CID: 57495353 TTD: DGO2C1
Compound Name	Atezolizumab		Approved	[16]
External Link	TTD: D0YM2K
Compound Name	Bavencio		Approved	[16]
External Link	TTD: D0W8HN
Compound Name	Tebentafusp		Approved	[47]
External Link	TTD: D0S0BJ
Compound Name	Merimepodib		Approved	[48]
Synonyms	Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid Click to Show/Hide
External Link	CID: 153241 TTD: D0F0ZE DrugBank: DB04862
Compound Name	Taxol		Approved	[49]
Synonyms	C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR,betaS),11alpha,12alpha,12aalpha,12balpha))- Click to Show/Hide
External Link	CID: 36314 TTD: D0C4RB DrugBank: DB01229
Compound Name	Ramucirumab		Approved	[50]
Synonyms	LY3009806 Click to Show/Hide
External Link	TTD: D09HVD
Compound Name	Tucatinib		Approved	[51]
Synonyms	Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE Click to Show/Hide
External Link	CID: 51039094 TTD: D09GRX DrugBank: DB11652
Compound Name	Antacids		Approved	[52]
External Link	TTD: D06AJL
Compound Name	Trastuzumab		Approved	[16]
Synonyms	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor) Click to Show/Hide
External Link	TTD: D04WFL
Compound Name	Carbamazepine		Phase 3	[53]
Synonyms	Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals Click to Show/Hide
External Link	CID: 2554 TTD: D04MSM DrugBank: DB00564
Compound Name	Margetuximab		Approved	[16]
External Link	TTD: D01YYP
Compound Name	Nivolumab		Approved	[16]
External Link	TTD: D00GOV
Compound Name	GRANITE		Phase 3	[54]
Synonyms	Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)- Click to Show/Hide
External Link	CID: 11784975 TTD: DKF9I3
Compound Name	Zolbetuximab		Phase 3	[55]
Synonyms	IMAB362 Click to Show/Hide
External Link	TTD: D4HQ1F
Compound Name	Tusamitamab ravtansine		Phase 3	[56]
Synonyms	SAR408701 Click to Show/Hide
External Link	TTD: D2D6NJ
Compound Name	Andecaliximab		Phase 3	[57]
External Link	TTD: D0Z6SP
Compound Name	ABP 980		Phase 3	[58]
External Link	TTD: D0WZ0X
Compound Name	GS-5745		Phase 3	[49]
External Link	CID: 56776542 TTD: D0WL0Q
Compound Name	S-1		Phase 3	[59]
Synonyms	Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate) Click to Show/Hide
External Link	CID: 163872 TTD: D0S8LJ
Compound Name	Lonsurf		Phase 3	[16]
External Link	TTD: D0PM0Y
Compound Name	GDC-0068		Phase 3	[49]
Synonyms	RG7440 Click to Show/Hide
External Link	CID: 24788740 TTD: D0I4TH DrugBank: DB11743
Compound Name	Edotecarin		Phase 3	[60]
Synonyms	ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione Click to Show/Hide
External Link	CID: 9808998 TTD: D0I1DW DrugBank: DB04882
Compound Name	RG3638		Phase 3	[61]
Synonyms	Onartuzumab Click to Show/Hide
External Link	TTD: D0H9PT
Compound Name	G17DT		Phase 3	[62]
Synonyms	Gastrimmune; Insegia Click to Show/Hide
External Link	TTD: D0G8ZQ
Compound Name	DE-766		Phase 3	[63]
External Link	TTD: D0FJ1W
Compound Name	Tesetaxel		Phase 2	[64]
Synonyms	DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE Click to Show/Hide
External Link	CID: 6918574 TTD: D0F9VH DrugBank: DB12019
Compound Name	Nelipepimut S		Phase 3	[65]
Synonyms	E75 Click to Show/Hide
External Link	CID: 9941306 TTD: D0F8UV
Compound Name	BMS-986205		Phase 3	[16]
Synonyms	KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)- Click to Show/Hide
External Link	CID: 121328278 TTD: D0DP5I DrugBank: DB14986
Compound Name	Rivoceranib		Phase 3	[16]
External Link	TTD: D0D7BX
Compound Name	Claudiximab		Phase 3	[16]
Synonyms	IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed Click to Show/Hide
External Link	TTD: D0B3ZC
Compound Name	OS-440		Phase 3	[66]
Synonyms	CNS modulator (spasticity), Osmotica Click to Show/Hide
External Link	TTD: D09OHH
Compound Name	Oraxol		Phase 3	[16]
External Link	TTD: D04UWU
Compound Name	ICI 118,551		Phase 3	[49]
Synonyms	Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R,S)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO Click to Show/Hide
External Link	CID: 3682 TTD: D04DJS
Compound Name	Evorpacept		Phase 2/3	[67]
Synonyms	ALX148 Click to Show/Hide
External Link	TTD: DRP8H0
Compound Name	BNT141		Phase 2	[68]
External Link	TTD: DFZ19J
Compound Name	Anti-LAG3		Phase 2	[58]
External Link	TTD: D0T7OI
Compound Name	GSK1292263		Phase 2	[69]
External Link	CID: 24996872 TTD: D0S4II DrugBank: DB12627
Compound Name	MM-111		Phase 2	[70]
External Link	TTD: D0Q2KM
Compound Name	Plevitrexed		Phase 2	[71]
Synonyms	ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid, Click to Show/Hide
External Link	CID: 135430970 TTD: D0I9GR DrugBank: DB06163
Compound Name	DS-8201		Phase 1	[58]
Synonyms	9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS- Click to Show/Hide
External Link	CID: 10671 TTD: D0E8IQ
Compound Name	XL880		Phase 2	[72]
Synonyms	GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors Click to Show/Hide
External Link	CID: 42642645 TTD: D0D1GF DrugBank: DB12307
Compound Name	Matuzumab		Phase 2	[73]
Synonyms	EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals Click to Show/Hide
External Link	TTD: D0BZ7V
Compound Name	BAY-57-9352		Phase 2	[49]
Synonyms	Telatinib; Bay 57-9352 Click to Show/Hide
External Link	CID: 9808844 TTD: D07NOI DrugBank: DB15393
Compound Name	Bemarituzumab		Phase 2	[74]
External Link	TTD: D05ISO
Compound Name	PEGPH20		Phase 2	[16]
External Link	TTD: D05INV
Compound Name	Plevitrexed (R)-isomer		Phase 2	[75]
Synonyms	YW3548 Click to Show/Hide
External Link	CID: 213022 TTD: D04FYZ
Compound Name	APR-246		Phase 2	[76]
Synonyms	Eprenetapopt Click to Show/Hide
External Link	CID: 52918385 TTD: D03XTY DrugBank: DB11684
Compound Name	CRS-207		Phase 2	[65]
External Link	TTD: D02WSB
Compound Name	Opdivo + Yervoy		Phase 3	[16]
External Link	TTD: D02VYE
Compound Name	CT-041		Phase 1/2	[77]
External Link	TTD: DJ6AW5
Compound Name	BPX-601		Phase 1/2	[78]
External Link	TTD: D0TY6U
Compound Name	Anti-MUC1 CAR-T cells		Phase 1/2	[79]
External Link	TTD: D0C9MJ
Compound Name	Anti-Mesothelin CAR-T cells		Phase 1/2	[80]
External Link	TTD: D0BE6M
Compound Name	Anti-HER2 CAR-T		Phase 1/2	[81]
External Link	TTD: D08QZH
Compound Name	CAR-T Cells targeting EpCAM		Phase 1/2	[82]
External Link	TTD: D08QYW
Compound Name	PAT-SC1		Phase 1/2	[83]
Synonyms	SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab Click to Show/Hide
External Link	TTD: D00UOQ
Compound Name	ASP2138		Phase 1	[84]
External Link	TTD: DTQL30
Compound Name	SAR443216		Phase 1	[85]
External Link	TTD: DL6F3E
Compound Name	AMG 199		Phase 1	[86]
External Link	TTD: DEP3Z8
Compound Name	AMG 910		Phase 1	[87]
External Link	TTD: DEDP81
Compound Name	Alofanib		Phase 1	[88]
Synonyms	1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid Click to Show/Hide
External Link	CID: 86280646 TTD: D47MOS
Compound Name	HER2-specific CAR T cell		Phase 1	[89]
External Link	TTD: D0YF6K
Compound Name	Anti-CEA-CAR T		Phase 1	[90]
External Link	TTD: D0S1QN
Compound Name	XR-5944		Phase 1	[91]
Synonyms	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942 Click to Show/Hide
External Link	CID: 439035 TTD: D0Q5TH DrugBank: DB06364
Compound Name	A168		Phase 1	[92]
External Link	TTD: D0L9PU
Compound Name	EGFR806-specific CAR T cell		Phase 1	[93]
External Link	TTD: D0I7ZH
Compound Name	AbGn-107		Phase 1	[16]
External Link	TTD: D08GZE
Compound Name	FPA144		Phase 1	[58]
External Link	TTD: D06NND
Compound Name	Minnelide 001		Phase 1	[49]
External Link	TTD: D05UFJ
Compound Name	CAR-T cells targeting EpCAM		Phase 1	[94]
External Link	TTD: D01TNK
Compound Name	Anti-CEA CAR-T cells		Phase 1	[95]
External Link	TTD: D00KDQ
Compound Name	EPCAM-targeted CAR-T cells		Clinical trial	[96]
External Link	TTD: D0T8DD
Compound Name	PMID28460551-Compound-1		Patented	[97]
External Link	CID: 25190990 TTD: D0IH3I DrugBank: DB14866
Compound Name	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1		Patented	[98]
Synonyms	PMID28621580-Compound-WO2012084683c62 Click to Show/Hide
External Link	TTD: D04PKQ
Compound Name	TOPIXANTRONE HYDROCHLORIDE		Discontinued in Phase 2	[99]
Synonyms	SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride Click to Show/Hide
External Link	CID: 6918273 TTD: D06DWQ
Compound Name	MDL 101,731		Discontinued in Phase 2	[100]
Synonyms	Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331 Click to Show/Hide
External Link	CID: 6435808 TTD: D05HZI DrugBank: DB06433
Compound Name	BBR-3438		Discontinued in Phase 2	[101]
Synonyms	Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438 Click to Show/Hide
External Link	CID: 3038512 TTD: D01VPR
Compound Name	IPI-493		Discontinued in Phase 1	[102]
Synonyms	[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851 Click to Show/Hide
External Link	CID: 9893658 TTD: D0BM6S DrugBank: DB13023
Compound Name	Kanjinti		Application submitted	[16]
External Link	TTD: D0CW3U
Compound Name	Anti-CD9 mab		Investigative	[103]
Synonyms	ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University Click to Show/Hide
External Link	TTD: D09BPT

References

Ref 1	Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer. Aging (Albany NY). 2021 Apr 21;13(8):12224-12238. doi: 10.18632/aging.103822. Epub 2021 Apr 21.
Ref 2	METTL3 Promotes the Proliferation and Mobility of Gastric Cancer Cells. Open Med (Wars). 2019 Mar 2;14:25-31. doi: 10.1515/med-2019-0005. eCollection 2019.
Ref 3	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
Ref 4	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 5	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
Ref 6	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 7	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. doi: 10.3816/CBC.2005.n.047.
Ref 8	Clinical pipeline report, company report or official report of Roche (2009).
Ref 9	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 10	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
Ref 11	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-1307. doi: 10.1093/annonc/mdp524. Epub 2009 Nov 16.
Ref 12	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. doi: 10.3816/CLML.2010.n.059.
Ref 13	A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344. doi: 10.3727/096504020X15825405463920. Epub 2020 Feb 24.
Ref 14	Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206. doi: 10.1002/cam4.3090. Epub 2020 Apr 28.
Ref 15	Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112. doi: 10.1038/s42003-020-01631-8.
Ref 16	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 17	Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8.
Ref 18	Clinical pipeline report, company report or official report of BeiGene.
Ref 19	National Cancer Institute Drug Dictionary (drug name LP-108).
Ref 20	ClinicalTrials.gov (NCT05024045) A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. U.S.National Institutes of Health.
Ref 21	Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287. doi: 10.3390/cells9051287.
Ref 22	Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. doi: 10.1007/s11095-004-1871-1.
Ref 23	Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32. doi: 10.1002/pros.10351.
Ref 24	Mcl-1 inhibitors: a patent review. Expert Opin Ther Pat. 2017 Feb;27(2):163-178. doi: 10.1080/13543776.2017.1249848. Epub 2016 Nov 17.
Ref 25	Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007 Feb 22;50(4):641-62.
Ref 26	WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83. doi: 10.1158/0008-5472.CAN-07-6590.
Ref 27	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. doi: 10.1021/jm060460o.
Ref 28	Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24. doi: 10.1021/jm010016f.
Ref 29	The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther. 2004 Dec;3(12):1513-24.
Ref 30	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7920).
Ref 31	Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906. doi: 10.1021/jm901446n.
Ref 32	TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 33	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 34	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. doi: 10.1080/14712598.2019.1572746. Epub 2019 Jan 29.
Ref 35	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. doi: 10.1038/s41573-020-00108-x. Epub 2021 Jan 19.
Ref 36	ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
Ref 37	National Cancer Institute Drug Dictionary (drug id 756211).
Ref 38	Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665. doi: 10.1021/acs.jmedchem.7b01375. Epub 2017 Dec 27.
Ref 39	Clinical pipeline report, company report or official report of HaiHe Biopharma.
Ref 40	EZH2 inhibitors: a patent review (2014-2016). Expert Opin Ther Pat. 2017 Jul;27(7):797-813. doi: 10.1080/13543776.2017.1316976. Epub 2017 Apr 20.
Ref 41	Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015). Expert Opin Ther Pat. 2016;26(3):309-22. doi: 10.1517/13543776.2016.1146252. Epub 2016 Feb 16.
Ref 42	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6. doi: 10.1038/nchembio.1084. Epub 2012 Sep 30.
Ref 43	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. doi: 10.1073/pnas.1210371110. Epub 2012 Dec 10.
Ref 44	An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-34. doi: 10.1021/cb400133j. Epub 2013 Apr 24.
Ref 45	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. doi: 10.1021/ml3003346. eCollection 2012 Dec 13.
Ref 46	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217759.
Ref 47	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228.
Ref 48	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 49	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 50	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7390).
Ref 51	ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
Ref 52	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 53	ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
Ref 54	ClinicalTrials.gov (NCT00879333) Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). U.S. National Institutes of Health.
Ref 55	ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
Ref 56	ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.
Ref 57	ClinicalTrials.gov (NCT02545504) Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1). U.S. National Institutes of Health.
Ref 58	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 59	Clinical pipeline report, company report or official report of Taiho Pharma U.S.A.
Ref 60	Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
Ref 61	ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.
Ref 62	ClinicalTrials.gov (NCT02118077) Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 63	Clinical pipeline report, company report or official report of Daiichi Sankyo.
Ref 64	ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 65	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 66	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031678)
Ref 67	ClinicalTrials.gov (NCT05002127) A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). U.S.National Institutes of Health.
Ref 68	ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 69	ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.
Ref 70	ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
Ref 71	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8278).
Ref 72	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
Ref 73	ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
Ref 74	ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
Ref 75	Clinical pipeline report, company report or official report of plevitrexed.
Ref 76	ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
Ref 77	ClinicalTrials.gov (NCT04404595) Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers. U.S.National Institutes of Health.
Ref 78	ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 79	ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Ref 80	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 81	ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 82	ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 83	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013314)
Ref 84	ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
Ref 85	Clinical pipeline report, company report or official report of Sanofi
Ref 86	ClinicalTrials.gov (NCT04117958) Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
Ref 87	ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health.
Ref 88	ClinicalTrials.gov (NCT04071184) Study of Alofanib in Patients With Metastatic Gastric Cancer. U.S. National Institutes of Health.
Ref 89	ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Ref 90	ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 91	Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
Ref 92	Clinical pipeline report, company report or official report of Klus Pharma
Ref 93	ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Ref 94	ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
Ref 95	ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 96	ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
Ref 97	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 98	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. doi: 10.1080/13543776.2017.1344215. Epub 2017 Jun 23.
Ref 99	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
Ref 100	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002544)
Ref 101	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)
Ref 102	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026781)
Ref 103	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.

m6A-centered Crosstalk Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map